ERYTHROPOIETIN IS THE PRIMARY HORMONE responsible for the survival, proliferation, and differentiation of erythroid precursors within the fetal liver and adult bone marrow (1-3). The major site of erythropoietin production in the adult is the kidney (1, 2). When transgenic mice expressing human erythropoietin (EPO)2 mRNA are rendered anemic, peritubular interstitial cells mainly within the inner cortex produce EPO (4) . Further, the colocalization of EPO and ecto-5 '-nucleotidase suggests that the cells producing EPO within the kidney are peritubular interstitial fibroblasts (5) . The liver also contributes to EPO production, but to a much lesser degree. When transgenic mice expressing human EPO mRNA are rendered anemic, production is observed in hepatocytes that line the central veins, whereas in nontransgenic mice, a cell morphologically similar to the peritubular interstitial cell of the kidney also expresses EPO (4) . Using reverse transcription-polymerase chain reaction (RT-PCR), EPO mRNA was detected in the spleen and lung of rats (6) . Finally, other extrarenal sites of EPO production include bone marrow macrophages (7) and early colony-forming cells (8) , umbilical cord monocytes differentiated into a macrophage phenotype in vitro (9) , as well as brain astrocytes (10) .
Red cell mass and plasma volume expand during normal gestation in women and other mammalian species such as the rat (11; and see citations therein). Because red cell life span is not altered during pregnancy (12) , increased erythropoiesis accounts for the expansion of red cell mass. Bioactive erythropoietin is elevated in the serum and urine of gravid women; immunoreactive EPO is also elevated in the serum or plasma of pregnant women and rats (11) . Thus, enhanced erythropoiesis is most likely due to increased circulating erythropoietin, although other hormones may contribute (see citations in ref 11 ). In the conscious gravid rat model, increased plasma EPO is secondary to enhanced metabolic production and not to reduced metabolic clearance (13) . Although the liver is believed to be the main site of EPO production in the fetus (14, 15) , significant fetal contribution to maternal EPO is unlikely because placental transport is either severely limited or altogether restricted (16) .
The organ localization of increased basal EPO production in pregnancy has not been identified. kidney is the main site of EPO production in adult animals, increased renal production is likely in pregnancy, albeit paradoxical in view of the substantial increases in renal blood flow (17, 18) , and consequently of oxygen delivery, which opposes erythropoietin production.
On the other hand, it is possible that increased renal oxygen consumption partly due to raised glomerular filtration (17, 18) , the "physiological anemia" of gestation (19) , and various circulating hormones or autocrine/paracrine factors (13) may potentiate EPO biosynthesis by the kidneys during pregnancy.
Nephrectomized gravid ewes failed to show a rise in plasma EPO in response to anemia suggesting that stimulated EPO production in pregnancy occurs in the kidneys (20) . However, the possibility that extrarenal sites of EPO production contribute to elevated basal levels in pregnancy cannot be discounted.
In the present work, we postulate a new site for EPO production; namely, the placenta, which may contribute to increased basal circulating levels of the hormone during pregnancy. To test this hypothesis, we investigated whether the human placenta expresses immunoreactive EPO and EPO mRNA as determined by immunohistochemistry, enzyme-linked immunosorbant assay (ELISA), and RT-PCR.
METHODS

Human placentas
Human placentas were obtained from women with normal pregnancies at term immediately after cesarian section for breech presentation or repeat cesarian section. Placentas were also collected from nulliparious women with the diagnosis of pt-eeclampsia immediately after cesarian section (no labor 
Immunocytochemistry
Two monoclonal mouse anti-EPO antibodies were used. One from Genzyme (Cambridge, Mass.) was generated against amino acids 1.26 of human EPO, and the other from StemCell Technologies (Vancouver, B.C.) was raised against pure human urinary EPO, which does not recognize the 1-26 amino acid epitope (25) . After permeabilization of the placental tissue sections or cultured cells with 0.3% Triton-X 100, quenching of endogenous peroxidase with 0.6% hydrogen peroxide in methanol, and blocking with normal horse serum, the specimens were incubated with either the Genzyme or StemCeIl antibody for 1 h at room temperature. Both antibodies were used at a concentration of 20 1g/ml, which proved to be optimal based on preliminary experiments. Negative controls were generated by substituting the same concentration of mouse lgG2ai
for the mouse anti-human EPO antibody from Genzyme or omitting the primary antibody (an IgE) for the mouse anti-human EPO were performed on adjacent tissue sections. On one section, the procedure for EPO was followed as described above. On the other, a mouse anti-human cytokeratin monoclonal antibody (0.875 Jig/mI; Sigma) or a prediluted rabbit antihuman placental lactogen antibody (hPL; DAKO) was used to localize extravillous cytotrophoblasts. Identical concentrations of mouse IgG1K or rabbit preimmune serum were stibstituted for the primary antibodies in order to generate negative controls. The hPL antibody was detected by the Vectastain Elite ABC Kit as described above, and the cytokeratin antibody was detected with an alkaline phosphatase conjugated secondary antibody and the substrate nitro-blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate in dimethylformamide.
Enzyme-linked immunosorbant assay
Immunoreactive EPO was determined in cell culture supernatants by ELISA (Quantikine IVD, R&D Systems, Minneapolis, Minn.). The capture antibody was a monoelonal generated against recombinant human EPO by Amgen. The lowest standard was 2.5 mU/mI. GeneAmp PCR System 9600 (Foster City, Calif.), the mixture was heated at 75#{176}C for 10 mm, slowly decreased to 42#{176}C over a 20 mm period, and sustained at this temperature for 15 mm. Reverse transcription was performed in a total volume of 20 l.il containing reverse transcription buffer (Promega, Madison, Wis.), DTT (10 mM), dNTP (1.0 mM), RNasin (20U; Promega), and AMV reverse transcriptase (5U; Promega). Using the Perkin Elmer GeneAmp PCR System 9600, the reaction was heated at 42#{176}C for 45 mm, followed by 99#{176}C for 5 mm to denature the enzyme. In preliminary experiments, we determined that 2
Jig of RNA yielded optimal PCR products. Nested primer PCR reaction was then performed.
The external primers were 5'-TGG CTG TGC CU CTC CTG-3' and 5'-CCT CTG TAC ACC TTC AGC-3' corresponding to the codons for amino acids 9-14 and 180-185, respectively.
The internal primers were 5'-CCA CGC CTC ATC TGT GAC-3' and 5'-CAG CAG CTG AGG CCG CAT-3' corresponding to the codons for amino acids were performed in a sodium phosphate/SDS buffer (27) . Hybridization proceeded overnight at 65#{176}C in glass cylinders, which were rotated in a Hybaid hybridization oven (National Labnet Co., Woodbridge, N.J.).
After washing of the membranes twice for 30 mm at 60#{176}C, autoradiography was performed for 1 h at -80#{176}C (Kodak X-OMAT AR film).
Northern analysis
Total RNA was extracted from cells or tissues and processed as described above. RNA samples were subjected to denaturing gel electrophoresis, transferred to Nylon membrane, cross-linked, and hybridized with the EPO cDNA probe (also described above). The membranes were exposed to film at -80#{176}C for 3-7 days.
Statistical analysis
For analysis of EPO expression by l-lep G2 and JAR choriocarcinoma cells, two-factor ANOVA was used, with time as one factor and P02 as the other. A P value of < 0.05 was taken to be significant.
RESULTS
Detection of EPO immunoreactivity
In first-trimester villous placenta ( Fig.  lA-F) , immunoreactive EPO was most intensely associated with the villous cytotrophoblast.
The syncytiotrophoblast was also immunoreactive, but generally to a lesser degree. In the second-trimester placenta ( Fig. 2A-F EPO was most intensely associated with cytotrophoblast cell columns (cytokeratin immunoreactive cells, Fig. 2,1 ; human placental lactogen immunoreactive cells, Fig. 2D ) and the syncytiotrophoblast.
Colocalization studies demonstrated that endovascular and intravascular cytotrophoblasts identified by human placental lactogen expression were also positive for EPO immunoreactivity in second-trimester placentas (data not shown). In the placentas from normal third-trimester and preeclamptic women, the syncytiotrophoblast and cells within the decidual basal plate showed EPO immunoreactivity (Fig.  3A-D) . EPO immunoreactivity was observed within cells of the villous core (Fig. 1, Fig. 2, Fig. 3 (Fig. 2) , although the latter generally produced less intense staining.
Hepatoma G2 (positive control) and JAR (trophoblast-derived) choriocarcinoma cells were subjected to hypoxia concurrently (15-20 torr) . Table  1 shows that hypoxia significantly increased immunoreactive EPO in the cell culture medium of both cell types.
Detection of EPO mRNA
On Northern analysis, the EPO cDNA probe hybridized with 20 .tg of total RNA extracted from hepatoma cells grown in ambient oxygen and hypoxic environments (positive control; Fig. 4 ). The hybridization signal was fainter for cells grown in ambient oxygen, but quite intense using the RNA extracted from the cells grown in hypoxia. The size was approximately 1.4 kb, the predicted size of the EPO mRNA. Comparable results were obtained for JAR (trophoblast-derived) choriocarcinoma cells (Fig. 4) . Despite loading as much as 50 .tg of total RNA from the placenta, we were unable to obtain a hybridization signal. Therefore, we used RT-PCR to detect placental EPO mRNA.
A 378 bp PCR product was amplified from reversed transcribed RNA extracted from hypoxic hepatomas cells, and from placentas of normal first-, second-, and thirdtrimester women as well as women with preeclampsia ( Fig. 5A, B) . The 378 bp PCR product matched the predicted size. Deletion of RNA or the reverse transcriptase from the reverse transcription reaction yielded no demonstrable bands either by ethidium bromide detection or Southern analysis (negative controls).
As additional evidence that the amplified 378 bp PCR product was derived from reverse transcribed EPO mRNA, restriction enzyme analysis was performed. The results obtained for hypoxic hepatoma cells and third-trimester villous placenta are depicted in Fig. 6A, B , respectively. The predicted and observed sizes of the restriction enzyme fragments were identical: Pvu II, 270
and 102 bp; Hinc II, 240 and 138 bp. These restriction enzyme fragments were observed for both the positive control, hypoxic hepatoma cells (Fig. 6A) , and the placenta (Fig. 6B) . The 378 bp PCR products shown on the agarose gel in Figs. 5A, B were subsequently transferred to nylon membrane and hybridized with the EPO cDNA probe (Southern analysis).
Intense hybridization with the 378 bp fragment was observed. Hybridization was also observed for the Pvu II 270 bp and Hinc II 240 bp restriction enzyme fragments in which the probe did not overlap with the primer sequences (data not shown). A 378 bp PCR product was also amplified from reverse transcribed RNA of cytotrophoblasts isolated from term placenta (Fig. oA, lane 6 ) and from the trophoblast-derived JAR choriocarcinoma cells (Fig. SC) .
DISCUSSION
Our objective was to determine whether the human placenta expresses erythropoietin. B.
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